Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05452239 · ClinicalTrials.gov registry record · Phase 4
A Study of Eptinezumab in Participants With Migraine and Medication Overuse Headache
A Phase 4 study, sponsored by H. Lundbeck A/S.
- Completed
- Registry status
- Phase 4
- Development phase
- 608
- Enrollment target
NCT05452239 is a Phase 4 study that has completed, run by H. Lundbeck A/S. The registered enrollment target is 608 participants.
The verdict
NCT05452239, a Phase 4 study, has completed, sponsored by H. Lundbeck A/S.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 608 participants
- Enrollment target
Study Summary
Medication overuse headache (MOH) is a type of headache caused by excessive use of acute headache or migraine medications (medications used to treat a headache or migraine once it begins). Treatment of MOH usually involves reducing the dose of or discontinuing acute medications. Eptinezumab is a medication used for the preventive treatment of migraine in adults. The main goals of this trial are to learn whether eptinezumab helps reduce the number of days with migraine, the number of days with headache, and acute medication use in adults who have migraine and MOH.
Interventions
- DRUG Placebo
- DRUG Eptinezumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 608 participants |
| Start Date | 2022-07-01 |
| Est. Completion | 2025-03-13 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05452239
The ClinicalTrials.gov registry entry for NCT05452239 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 608 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lundbeck A/S, which has 72 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05452239 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05452239 about?
NCT05452239 is a clinical study titled "A Study of Eptinezumab in Participants With Migraine and Medication Overuse Headache". Medication overuse headache (MOH) is a type of headache caused by excessive use of acute headache or migraine medications (medications used to treat a headache or migraine once it begins). Treatment of MOH usually involves reducing the dose of or discontinuing acute medications. Eptinezumab is a me...
What is the current status of trial NCT05452239?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 608 participants. The study started on 2022-07-01. Estimated completion is 2025-03-13.
What interventions are being tested in trial NCT05452239?
The interventions under investigation include: Placebo (DRUG), Eptinezumab (DRUG).
Who is sponsoring clinical trial NCT05452239?
This trial is sponsored by H. Lundbeck A/S, which has 72 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.